Targeted drug trial offers new hope for Tough-to-Treat cancers
NCT ID NCT04439136
Summary
This study is testing whether a drug called afatinib can help people with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers are enrolling about 40 patients whose cancers have stopped responding to standard treatments to see if afatinib can shrink their tumors or stop the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.